CHA2DS2-VASc score predicts atrial fibrillation recurrence after cardioversion: Systematic review and individual patient pooled meta-analysis.
CHA2DS2-VASc
arrhythmia
atrial fibrillation
cardioversion
recurrence
Journal
Clinical cardiology
ISSN: 1932-8737
Titre abrégé: Clin Cardiol
Pays: United States
ID NLM: 7903272
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
15
10
2018
revised:
12
12
2018
accepted:
27
12
2018
pubmed:
1
1
2019
medline:
6
6
2019
entrez:
1
1
2019
Statut:
ppublish
Résumé
Despite progresses in the treatment of the thromboembolic risk related to atrial fibrillation (AF), the management of recurrences remains a challenge. To assess if congestive heart failure or left ventricular systolic dysfunction (CHA Systematic review and individual patient pooled meta-analysis following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. observational trials in patients with AF undergoing cardioversion, available data on recurrence of AF and available data on CHA Overall, we collect data of 2889 patients: 61% were male, 50% with hypertension, 12% with diabetes, and 23% with history of ischemic heart disease. The median CHA2DS2-VASc score was 2.. At the multivariate analysis, chronic kidney disease (odds ratio [OR] 1.94; 95% confidence interval [CI] 1.12-3.27; P = 0.01), peripheral artery disease (OR 1.65; 95% CI 1.23-2.19; P < 0,0001), previous use of beta blockers (OR 1.5; 95% CI 1.19-1.88; P < 0.0001), and CHA2DS2-VASc score > 2 (OR 1.37; 95% CI 1.1-1.68; P = 0.002) were independent predictors of early recurrence of AF. CHA2DS2-VASc score predicts early recurrence of AF in the first 30 days after electrical or pharmacological cardioversion. Protocol registration PROSPERO (CRD42017075107).
Sections du résumé
BACKGROUND
BACKGROUND
Despite progresses in the treatment of the thromboembolic risk related to atrial fibrillation (AF), the management of recurrences remains a challenge.
HYPOTHESIS
OBJECTIVE
To assess if congestive heart failure or left ventricular systolic dysfunction (CHA
METHODS
METHODS
Systematic review and individual patient pooled meta-analysis following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines.
INCLUSION CRITERIA
METHODS
observational trials in patients with AF undergoing cardioversion, available data on recurrence of AF and available data on CHA
RESULTS
RESULTS
Overall, we collect data of 2889 patients: 61% were male, 50% with hypertension, 12% with diabetes, and 23% with history of ischemic heart disease. The median CHA2DS2-VASc score was 2.. At the multivariate analysis, chronic kidney disease (odds ratio [OR] 1.94; 95% confidence interval [CI] 1.12-3.27; P = 0.01), peripheral artery disease (OR 1.65; 95% CI 1.23-2.19; P < 0,0001), previous use of beta blockers (OR 1.5; 95% CI 1.19-1.88; P < 0.0001), and CHA2DS2-VASc score > 2 (OR 1.37; 95% CI 1.1-1.68; P = 0.002) were independent predictors of early recurrence of AF.
CONCLUSIONS
CONCLUSIONS
CHA2DS2-VASc score predicts early recurrence of AF in the first 30 days after electrical or pharmacological cardioversion. Protocol registration PROSPERO (CRD42017075107).
Identifiants
pubmed: 30597581
doi: 10.1002/clc.23147
pmc: PMC6712331
doi:
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
358-364Informations de copyright
© 2018 The Authors. Clinical Cardiology Published by Wiley Periodicals, Inc.
Références
Am Heart J. 2013 Sep;166(3):442-8
pubmed: 24016492
Clin Cardiol. 2019 Mar;42(3):358-364
pubmed: 30597581
Arch Intern Med. 2005 Feb 14;165(3):258-62
pubmed: 15710787
Eur Heart J. 2016 Oct 7;37(38):2893-2962
pubmed: 27567408
Am J Med. 2016 Aug;129(8):843-9
pubmed: 27012854
Eur Heart J Qual Care Clin Outcomes. 2017 Jul 1;3(3):192-197
pubmed: 28838088
Heart Rhythm. 2011 Aug;8(8):1160-6
pubmed: 21419237
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Evid Based Med. 2014 Dec;19(6):222-3
pubmed: 25147301
Circulation. 1997 Oct 7;96(7):2455-61
pubmed: 9337224
N Engl J Med. 1998 Sep 3;339(10):659-66
pubmed: 9725923
N Engl J Med. 2002 Dec 5;347(23):1825-33
pubmed: 12466506
Circulation. 2016 Aug 23;134(8):599-610
pubmed: 27550968
Anadolu Kardiyol Derg. 2013 Mar;13(2):123-30
pubmed: 23228974
Eur Heart J. 2018 Mar 1;39(9):763-816
pubmed: 28886620
J Am Heart Assoc. 2014 Nov 17;3(6):e001270
pubmed: 25404190
BMJ. 2009 Jul 21;339:b2700
pubmed: 19622552
Contemp Clin Trials. 2015 Nov;45(Pt A):139-45
pubmed: 26343745
Eur Heart J Acute Cardiovasc Care. 2018 Apr;7(3):264-274
pubmed: 27708110
Ann Noninvasive Electrocardiol. 2010 Jul;15(3):209-17
pubmed: 20645962
Heart Rhythm. 2018 Jul;15(7):971-979
pubmed: 29477974
Eur Respir J. 2003 Jun;21(6):1012-6
pubmed: 12797497
Ann Intern Med. 2007 Jun 19;146(12):857-67
pubmed: 17577005
Cardiovasc Res. 2005 Sep 1;67(4):655-66
pubmed: 15913581
Pacing Clin Electrophysiol. 2013 Jan;36(1):122-33
pubmed: 22978656
Lancet. 1999 Nov 27;354(9193):1896-900
pubmed: 10584742
Am J Cardiol. 2017 Mar 1;119(5):749-752
pubmed: 28017305
Intern Med J. 2017 Mar;47(3):275-279
pubmed: 27860070
Am J Emerg Med. 2016 Aug;34(8):1486-90
pubmed: 27292602
Chest. 2004 Aug;126(2):476-86
pubmed: 15302734
Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):335-41
pubmed: 25274966
J Atr Fibrillation. 2012 Jun 15;5(1):448
pubmed: 28496746
Lancet. 2015 Jul 11;386(9989):154-62
pubmed: 25960110
Clin Res Cardiol. 2013 Oct;102(10):713-23
pubmed: 23812041
N Engl J Med. 2002 Dec 5;347(23):1834-40
pubmed: 12466507
Chest. 2010 Feb;137(2):263-72
pubmed: 19762550
J Cardiovasc Med (Hagerstown). 2014 Aug;15(8):636-41
pubmed: 24978663
Circulation. 2000 Jan 18;101(2):194-9
pubmed: 10637208
Lancet. 2014 Mar 15;383(9921):955-62
pubmed: 24315724
J Am Coll Cardiol. 2014 Dec 2;64(21):e1-76
pubmed: 24685669
BMJ. 2003 Sep 6;327(7414):557-60
pubmed: 12958120